Andrew Berens
Stock Analyst at Leerink Partners
(1.38)
# 3,387
Out of 4,877 analysts
125
Total ratings
47%
Success rate
-9.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.36 | +22.28% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $2.60 | +130.77% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $33.26 | +68.37% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $13.35 | +117.23% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $128.18 | -24.33% | 24 | May 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $7.18 | +178.55% | 4 | Jan 5, 2023 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $69.88 | +13.05% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.51 | +232.89% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $6.26 | +538.98% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $1.43 | +4,585.31% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $140 | $76.30 | +83.49% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $1 | $0.37 | +172.41% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.39 | +1,280.75% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $12.55 | +99.20% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $110.87 | -13.41% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $68.10 | +14.54% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $52.60 | -8.75% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $11.39 | +145.83% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.16 | +2,227.59% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $1.26 | +2,290.44% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.51 | +343.46% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.12 | +388.28% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.28 | -13.79% | 7 | Jul 14, 2017 |
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.36
Upside: +22.28%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $2.60
Upside: +130.77%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $33.26
Upside: +68.37%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $13.35
Upside: +117.23%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $128.18
Upside: -24.33%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $7.18
Upside: +178.55%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $69.88
Upside: +13.05%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.51
Upside: +232.89%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.26
Upside: +538.98%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.43
Upside: +4,585.31%
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $76.30
Upside: +83.49%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.37
Upside: +172.41%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.39
Upside: +1,280.75%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $12.55
Upside: +99.20%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $110.87
Upside: -13.41%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $68.10
Upside: +14.54%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $52.60
Upside: -8.75%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $11.39
Upside: +145.83%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.16
Upside: +2,227.59%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $1.26
Upside: +2,290.44%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.51
Upside: +343.46%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $5.12
Upside: +388.28%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.28
Upside: -13.79%